Symproic (naldemedine) / Shionogi, Collegium Pharma  >>  Phase 3
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Symproic (naldemedine) / Shionogi, Collegium Pharma
NCT01965158 / 2013-002241-11: Efficacy and Safety of Naldemedine in the Treatment of Opioid-induced Constipation

Completed
3
547
US, Europe
Naldemedine, S 297995, Symproic®, Placebo
Shionogi
Opioid-induced Constipation
01/15
01/15
NCT01993940 / 2013-002948-91: Efficacy and Safety of Naldemedine in Treating Opioid-induced Constipation

Completed
3
553
US
Naldemedine, S-297995, Symproic®, Placebo
Shionogi
Opioid-induced Constipation
06/15
06/15
NCT01965652 / 2013-002949-11: Long Term Safety of Naldemedine

Completed
3
1246
US, Canada, Europe, RoW
Naldemedine, S-297995, Symproic®, Placebo
Shionogi
Opioid-induced Constipation
01/16
01/16
2021-000069-34: The effects of peripheral opioid receptor antagonism on recurrent acute pancreatitis Effekten af perifer opioid antagonisme på recidiverende akut pankreatitis

Ongoing
2/3
120
Europe
Naldemedine 0.2mg Film-coated Tablet, Film-coated tablet
Mech-Sense, Aalborg University Hospital, The Novo Nordisk Foundation, Shionogi B.V.
Recurrent acute pancreatitis, Recurrent acute inflammation of the pancreas, Diseases [C] - Digestive System Diseases [C06]
 
 
NCT04966559 / 2021-000069-34: Effects of a Peripherally Acting µ-opioid Receptor Antagonist on Recurrent Acute Pancreatitis

Active, not recruiting
2/3
74
Europe
Placebo treatment, Naldemedine 0.2 MG Oral Tablet
Asbjørn Mohr Drewes, Odense University Hospital, Hvidovre University Hospital, University Hospital Bispebjerg and Frederiksberg, Karolinska University Hospital
Pancreatitis, Acute
03/24
06/24

Download Options